More is not always better
Author:
Affiliation:
1. University of Verona
Publisher
American Society of Hematology
Link
https://ashpublications.org/blood/article-pdf/144/10/1033/2240686/blood_bld-2024-025289-c-main.pdf
Reference10 articles.
1. Randomized bendamustine-rituximab(R) + bortezomib induction and R + lenalidomide maintenance for mantle cell lymphoma;Smith;Blood,2024
2. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma;Wang;N Engl J Med,2022
3. Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts;Martin;J Clin Oncol,2023
4. Induction and maintenance therapy in elderly patients with mantle cell lymphoma: double-randomized MCL R2 elderly clinical trial by the European Mantle Cell Lymphoma Network;Ribrag;Blood,2023
5. Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma;Albertsson-Lindblad;Blood,2016
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3